Evotec SE Reports Q3 Revenue of €164.9 Million, Slightly Exceeding Expectations
Evotec SE has released its third-quarter financial results, reporting revenue of €164.9 million. This figure represents a slight beat over previous expectations of €164.2 million. For the first nine months of the year, the company's cumulative revenue reached €465.0 million. Despite the revenue beat, the company reported an adjusted Group EBITDA loss of €1.6 million for the third quarter and a nine-month loss of €44.3 million. These figures reflect the ongoing operational costs associated with the company's drug discovery and development services.
Topics: financial performance quarterly earnings revenue beat